# Review of advances in CAR-T therapies in malignant hematology

## TL;DR

This review summarizes key developments in CAR-T therapies for blood cancers, including approvals, long-term data, and strategies to overcome resistance.

## Contribution

The paper provides a comprehensive overview of recent advancements and resistance mechanisms in CAR-T therapies for hematologic malignancies.

## Key findings

- Pivotal studies led to the approval of CAR-T therapies for hematologic malignancies.
- Long-term and real-world data on CAR-T therapies are now available.
- Mechanisms of resistance and potential novel therapies to overcome them are examined.

## Abstract

There have been numerous advancements in immune cell effector therapies in the malignant hematology space. This review article explores the pivotal studies that led to the approval of chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and highlights available associated long-term and real-world data. It also examines the mechanisms of resistance and potential novel therapies to overcome these mechanisms.